Compare $GALT vs $SPRY | Chartloom

Compare

$GALT vs $SPRY

Galectin Therapeutics Inc · ARS Pharmaceuticals Inc

GALT

Galectin Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Compare $GALT vs $SPRY

Comparing Galectin Therapeutics Inc and ARS Pharmaceuticals Inc

GALTGalectin Therapeutics Inc

SPRYARS Pharmaceuticals Inc

GALTGalectin Therapeutics Inc

Market cap

$259M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-2.7%

52W performance

-16.9%

FCF yield

-6.1%

SPRYARS Pharmaceuticals Inc

Market cap

$420M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.81x

Rev growth (TTM)

4.1%

YTD performance

-63.2%

52W performance

-61.9%

FCF yield

-46.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GALT

SPRY

Detailed metrics comparison

GALT

Galectin Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

GALT$259M

SPRY$420M

Enterprise Value

GALT$384M

SPRY$509M

Price

GALT$3.94

SPRY$4.23

P/E Ratio

GALTN/A

SPRYN/A

P/S Ratio

GALT0.00x

SPRY3.59x

EV/Sales

GALT0.00x

SPRY4.35x

EV/EBITDA

GALT0.00x

SPRY0.00x

P/B Ratio

GALT150.12x

SPRY32.35x

P/FCF Ratio

GALTN/A

SPRYN/A

EV/FCF

GALT-24.16x

SPRY-2.59x

PEG Ratio

GALTN/A

SPRYN/A

Forward P/E (NTM)

GALTN/A

SPRYN/A

Forward P/S (NTM)

GALTN/A

SPRY2.81x

Revenue (TTM)

GALT$0

SPRY$117M

Revenue Growth (YoY)

GALTN/A

SPRY4.1%

Forward Rev Growth

GALT0.0%

SPRY46.9%

Gross Margin (TTM)

GALT0.0%

SPRY71.4%

Operating Margin (TTM)

GALT0.0%

SPRY0.0%

EBITDA Margin (TTM)

GALT0.0%

SPRY-183.6%

Net Margin (TTM)

GALT0.0%

SPRY-184.2%

FCF Margin (TTM)

GALTN/A

SPRY-168.1%

Net Income (TTM)

GALT$-28M

SPRY$-215M

FCF (TTM)

GALT$-16M

SPRY$-197M

EPS (TTM)

GALT-$0.43

SPRY-$2.17

ROE (TTM)

GALT-25862.0%

SPRY-25667.0%

ROA (TTM)

GALT-17683.0%

SPRY-6963.0%

ROIC (TTM)

GALT-11607.0%

SPRY-11943.0%

Cash

GALT$13M

SPRY$8M

Debt

GALT$138M

SPRY$97M

Net Cash/Debt

GALT$-124M

SPRY$-89M

Current Ratio (TTM)

GALT0.10x

SPRY3.48x

Quick Ratio (TTM)

GALT0.09x

SPRY3.13x

Debt/Equity (TTM)

GALT11.09x

SPRY7.73x

Debt/Assets (TTM)

GALT0.0%

SPRY0.0%

Interest Coverage (TTM)

GALTN/A

SPRYN/A

Net Debt/EBITDA (TTM)

GALT0.00x

SPRY0.00x

Beta

GALT0.50

SPRY0.92

52W Performance

GALT-16.9%

SPRY-61.9%

YTD Performance

GALT-2.7%

SPRY-63.2%

% from 52W High

GALT-44.7%

SPRY-67.8%

% from 52W Low

GALT94.6%

SPRY6.1%

Asset Turnover (TTM)

GALT0.00x

SPRY0.38x

FCF Yield (TTM)

GALT-6.1%

SPRY-46.8%

Earnings Yield (TTM)

GALT-10.8%

SPRY-51.3%

Dividend Yield (TTM)

GALTN/A

SPRYN/A

Rule of 40

GALT0.0

SPRY-164.1

EV/GP/RG

GALTN/A

SPRY0.16

Ticker research

View GALT research View SPRY research

Metric	GALT Galectin Therapeutics Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$259M	$420M
Enterprise Value	$384M	$509M
Price	$3.94	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.59x
EV/Sales	0.00x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	150.12x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.16x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.81x
Revenue & Growth
Revenue (TTM)	$0	$117M
Revenue Growth (YoY)	N/A	4.1%
Forward Rev Growth	0.0%	46.9%
Profitability
Gross Margin (TTM)	0.0%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-183.6%
Net Margin (TTM)	0.0%	-184.2%
FCF Margin (TTM)	N/A	-168.1%
Net Income (TTM)	$-28M	$-215M
FCF (TTM)	$-16M	$-197M
EPS (TTM)	-$0.43	-$2.17
ROE (TTM)	-25862.0%	-25667.0%
ROA (TTM)	-17683.0%	-6963.0%
ROIC (TTM)	-11607.0%	-11943.0%
Financial Health
Cash	$13M	$8M
Debt	$138M	$97M
Net Cash/Debt	$-124M	$-89M
Current Ratio (TTM)	0.10x	3.48x
Quick Ratio (TTM)	0.09x	3.13x
Debt/Equity (TTM)	11.09x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	0.92
52W Performance	-16.9%	-61.9%
YTD Performance	-2.7%	-63.2%
% from 52W High	-44.7%	-67.8%
% from 52W Low	94.6%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.38x
FCF Yield (TTM)	-6.1%	-46.8%
Earnings Yield (TTM)	-10.8%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-164.1
EV/GP/RG	N/A	0.16
Ticker research	View GALT research	View SPRY research

Valuation

P/S Ratio

GALT

0.00x

SPRY

3.59x

EV/FCF

GALT

-24.16x

SPRY

-2.59x

Growth & revenue

Revenue Growth TTM

SPRY

4.1%

Forward Revenue Growth

SPRY

46.9%

GALT

0.0%

Profitability & performance

Gross Margin

SPRY

71.4%

GALT

0.0%

ROE

SPRY

-25667.0%

GALT

-25862.0%

FCF Yield %

GALT

-6.1%

SPRY

-46.8%

52-Week Performance

GALT

-16.9%

SPRY

-61.9%

Detailed metrics comparison

GALT

Galectin Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

GALT$259M

SPRY$420M

Enterprise Value

GALT$384M

SPRY$509M

Price

GALT$3.94

SPRY$4.23

P/E Ratio

GALTN/A

SPRYN/A

P/S Ratio

GALT0.00x

SPRY3.59x

EV/Sales

GALT0.00x

SPRY4.35x

EV/EBITDA

GALT0.00x

SPRY0.00x

P/B Ratio

GALT150.12x

SPRY32.35x

P/FCF Ratio

GALTN/A

SPRYN/A

EV/FCF

GALT-24.16x

SPRY-2.59x

PEG Ratio

GALTN/A

SPRYN/A

Forward P/E (NTM)

GALTN/A

SPRYN/A

Forward P/S (NTM)

GALTN/A

SPRY2.81x

Revenue (TTM)

GALT$0

SPRY$117M

Revenue Growth (YoY)

GALTN/A

SPRY4.1%

Forward Rev Growth

GALT0.0%

SPRY46.9%

Gross Margin (TTM)

GALT0.0%

SPRY71.4%

Operating Margin (TTM)

GALT0.0%

SPRY0.0%

EBITDA Margin (TTM)

GALT0.0%

SPRY-183.6%

Net Margin (TTM)

GALT0.0%

SPRY-184.2%

FCF Margin (TTM)

GALTN/A

SPRY-168.1%

Net Income (TTM)

GALT$-28M

SPRY$-215M

FCF (TTM)

GALT$-16M

SPRY$-197M

EPS (TTM)

GALT-$0.43

SPRY-$2.17

ROE (TTM)

GALT-25862.0%

SPRY-25667.0%

ROA (TTM)

GALT-17683.0%

SPRY-6963.0%

ROIC (TTM)

GALT-11607.0%

SPRY-11943.0%

Cash

GALT$13M

SPRY$8M

Debt

GALT$138M

SPRY$97M

Net Cash/Debt

GALT$-124M

SPRY$-89M

Current Ratio (TTM)

GALT0.10x

SPRY3.48x

Quick Ratio (TTM)

GALT0.09x

SPRY3.13x

Debt/Equity (TTM)

GALT11.09x

SPRY7.73x

Debt/Assets (TTM)

GALT0.0%

SPRY0.0%

Interest Coverage (TTM)

GALTN/A

SPRYN/A

Net Debt/EBITDA (TTM)

GALT0.00x

SPRY0.00x

Beta

GALT0.50

SPRY0.92

52W Performance

GALT-16.9%

SPRY-61.9%

YTD Performance

GALT-2.7%

SPRY-63.2%

% from 52W High

GALT-44.7%

SPRY-67.8%

% from 52W Low

GALT94.6%

SPRY6.1%

Asset Turnover (TTM)

GALT0.00x

SPRY0.38x

FCF Yield (TTM)

GALT-6.1%

SPRY-46.8%

Earnings Yield (TTM)

GALT-10.8%

SPRY-51.3%

Dividend Yield (TTM)

GALTN/A

SPRYN/A

Rule of 40

GALT0.0

SPRY-164.1

EV/GP/RG

GALTN/A

SPRY0.16

Ticker research

View GALT research View SPRY research

Metric	GALT Galectin Therapeutics Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$259M	$420M
Enterprise Value	$384M	$509M
Price	$3.94	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.59x
EV/Sales	0.00x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	150.12x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.16x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.81x
Revenue & Growth
Revenue (TTM)	$0	$117M
Revenue Growth (YoY)	N/A	4.1%
Forward Rev Growth	0.0%	46.9%
Profitability
Gross Margin (TTM)	0.0%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-183.6%
Net Margin (TTM)	0.0%	-184.2%
FCF Margin (TTM)	N/A	-168.1%
Net Income (TTM)	$-28M	$-215M
FCF (TTM)	$-16M	$-197M
EPS (TTM)	-$0.43	-$2.17
ROE (TTM)	-25862.0%	-25667.0%
ROA (TTM)	-17683.0%	-6963.0%
ROIC (TTM)	-11607.0%	-11943.0%
Financial Health
Cash	$13M	$8M
Debt	$138M	$97M
Net Cash/Debt	$-124M	$-89M
Current Ratio (TTM)	0.10x	3.48x
Quick Ratio (TTM)	0.09x	3.13x
Debt/Equity (TTM)	11.09x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	0.92
52W Performance	-16.9%	-61.9%
YTD Performance	-2.7%	-63.2%
% from 52W High	-44.7%	-67.8%
% from 52W Low	94.6%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.38x
FCF Yield (TTM)	-6.1%	-46.8%
Earnings Yield (TTM)	-10.8%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-164.1
EV/GP/RG	N/A	0.16
Ticker research	View GALT research	View SPRY research